Technical Data
T8175-08
TRAIL (TNF-Related Apoptosis Inducing Ligand, Apo2L, TL2, TNFSF10)
Description:
Apoptosis, the process of programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms and involves dramatic changes in cellular structure. Apoptosis can be induced by certain cytokines including TNF and Fas (CD95L) of the TNF ligand family through interaction with their death domain (DD)-containing receptors, TNFR1 and Fas (CD95). A novel member in the TNF ligand family was recently identified and designated TRAIL (for TNF-related apoptosis-inducing ligand) and Apo2L. TRAIL is a type II membrane protein and expressed in a variety of human tissues. Two death domain containing receptors DR4 and DR5 have been identified as the receptor for TRAIL (47) as well as two decoy receptor designated DcR1 (TRID or TRAIL-R3) and DcR2 (TRUNDD or TRAIL-R4) that inhibits TRAIL function. The multiple receptors suggest a complex role for regulation of signalling by this cytokine. Like TNF and Fas, TRAIL induces apoptosis and NF-kappaB activation in many tissues and cells.

Applications:
Suitable for use in Flow Cytometry, Immunocytochemistry, Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry: Frozen
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGSerum
SizeStorageShippingSourceHost
100ul-20CBlue IceHumanRabbit
Concentration:
Not Determined
Immunogen:
Recombinant human soluble TRAIL (aa 95-281)
Purity:
Serum
Form
Supplied as a liquid in 0.02% sodium azide.
Specificity:
Recognizes human soluble TRAIL. Does not cross-react with mouse TRAIL.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.C.M. Schempp, et al.; FEBS Lett. 493, 26 (2001) Abstract2. H. Dong, et al.; Nat. Med. 8, 793 (2002) Abstract